Purchase this article with an account.
K.D. Godeiro, A.N. Odashiro, N. Gans, S. Callejo, D.N. Odashiro, M.N. Burnier, Jr.; Immunohistochemical Panel for the Identification of Poorly Differentiated Orbital Metastatic Tumors . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4687.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Orbital metastases (OM) occur in 2–3% of patients with systemic cancer and may be the first indication of an occult tumor in 19% of these patients. Metastatic carcinoma from different locations can have similar microscopic appearances, which confound the identification of the primary site. In these cases, histopathological examination with immunohistochemical markers may be helpful to indicate the origin of the metastastic tumor. The purpose of this study was to examine the applicability of an immunohistochemical panel of seven monoclonal antibodies to identify the primary site of poorly differentiated orbital metastatic carcinomas.
Immunohistochemistry was performed to detect cytokeratin (CK) 7, CK20, thyroid transcription factor–1 (TTF–1), BRST1, BRST2, carcinoembryonic antigen (CEA) and prostate– specific antigen (PSA) in 7 cases of poorly differentiated orbital metastases. Of the seven cases, four were female and three male. The youngest patient was thirty–six while the oldest was eighty–eight years of age.
The immunohistochemical panel alone was helpful to identify the primary source of the metastatic lesion in 3 out of the 7 cases. Two of them were metastatic breast carcinomas (BRST1, BRST2 positive) and one was a prostate carcinoma (PSA positive). By correlating the immunohistochemical results with the previous clinical history, the primary site could be identified in 2 more cases. In those metastatic lesions, the positive staining for CK7, CK20, and CEA, associated with negative staining for BRST1, BRST2, PSA and TTF–1, indicated bladder as the probable primary site. In 2 out of 7 cases, the metastatic tumor was only positive for CEA, therefore a primary site could not be identified.
An immunohistochemical panel of poorly differentiated orbital metastases is helpful in the identification of the primary tumor site. The association of seven markers with the patient’s clinical history allowed for the positive identification of the primary tumor in the majority of these cases.
This PDF is available to Subscribers Only